Murali Ramaswamy, MD
Pulmonary Disease · Greensboro, NCNPI 1013994797
Payments from drug & device makers
Across 882 payments — averaging $2261.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$632K
- United Therapeutics Corporation$613K
- Boehringer Ingelheim$388K
- Roche Products Limited$188K
- Astrazeneca UK Limited$82K
- Emergent Biosolutions Inc.$25K
- plus $66K from 29 others
Across 9 payments — averaging $217.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 152 | $631,851 |
| United Therapeutics Corporation | 361 | $612,971 |
| Boehringer Ingelheim | 82 | $387,787 |
| Roche Products Limited | 38 | $188,051 |
| Astrazeneca UK Limited | 1 | $82,495 |
| Emergent Biosolutions Inc. | 6 | $25,428 |
| Kadmon Corporation LLC | 5 | $25,100 |
| Regeneron | 4 | $21,150 |
| GSK | 62 | $9,276 |
| Genentech USA, Inc. | 21 | $5,958 |
| Sanofi US Services Inc. | 1 | $1,125 |
| AstraZeneca | 41 | $925 |
| F. Hoffmann-la Roche AG | 1 | $621 |
| Insmed, Inc. | 12 | $292 |
| Novartis | 18 | $278 |
| Amgen | 8 | $180 |
| Merck | 10 | $159 |
| Grifols USA, LLC | 7 | $155 |
| Actelion Pharmaceuticals US, Inc. | 6 | $106 |
| Mylan Specialty L.p. | 6 | $101 |
| Sanofi | 3 | $97 |
| Regeneron Healthcare Solutions, Inc. | 3 | $75 |
| Vifor Pharma, Inc. | 3 | $68 |
| Inogen, Inc. | 7 | $64 |
| Verona Pharma, Inc. | 3 | $58 |
| Mallinckrodt Hospital Products Inc. | 3 | $56 |
| Viatris Specialty LLC | 3 | $52 |
| AbbVie(2 entities) | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 4 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Shionogi Inc | 2 | $37 |
| Baxter Healthcare | 1 | $25 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Teleflex LLC | 1 | $11 |
How this compares
$1,994,708 in reported general payments places this provider in the 95th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Greensboro
- Michael WertGreensboro$412K
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Anup BanerjeeGastonia$2.1M
- Hubert FordChapel Hill$2M
- Mikell JarrattGastonia$1.7M
- Lake MorrisonDurham$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.